The first global all organ company
Founded in 1998, XVIVO is the only medical technology company
dedicated to extending the life of all major organs – so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine.
We are committed to providing our customers with solutions and systems that can improve the transplant process outcome, facilitate the work for the transplant team, and enhance the long-term outcomes and quality of life of the transplant recipient.
We believe nobody should die waiting for a new organ.
Founded in 1998, XVIVO is the only medical technology company
dedicated to extending the life of all major organs – so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine.
We are committed to providing our customers with solutions and systems that can improve the transplant process outcome, facilitate the work for the transplant team, and enhance the long-term outcomes and quality of life of the transplant recipient.
We believe nobody should die waiting for a new organ.
Location: Sweden, Gothenburg
Employees: 51-200
Founded date: 1998
Investors 1
| Date | Name | Website |
| 17.05.2025 | Cowtown An... | cowtownang... |
Mentions in press and media 9
| Date | Title | Description |
| 26.01.2023 | Report on Operations 2022 | GOTHENBURG, SWEDEN / ACCESSWIRE / January 26, 2023 / XVIVO Perfusion AB XVIVO(LSE:0RKL)(FRA:3XV) Fourth quarter 2022 (October 1 - December 31) Net sales amounted to SEK 131.5 million (85.9), corresponding to an increase of 53 percent in SEK... |
| 16.01.2023 | XVIVO presents Report on Operations 2022 | GOTHENBURG, SE / ACCESSWIRE / January 16, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the Report on operations 2022. The presentation will be held in En... |
| 30.12.2022 | Increased Number of Shares and Votes in XVIVO Perfusion AB (publ) | GOTHENBURG, SE / ACCESSWIRE / December 30, 2022 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) As of today, 30 December 2022, the total number of shares and votes in XVIVO Perfusion AB (publ) is 29,831,919. The number of shares and vot... |
| 30.11.2022 | Christoffer Rosenblad appointed as CEO of XVIVO | GOTHENBURG, SWEDEN / ACCESSWIRE / November 30, 2022 / XVIVO Perfusion AB XVIVO (LSE:0RKL) (FRA:3XV) The board of XVIVO Perfusion AB (publ) ("XVIVO") has appointed Christoffer Rosenblad as CEO. Christoffer has had the role of actin... |
| 19.05.2022 | CHU Toulouse in France Starts Liver and Lung Perfusion Programs Using XVIVO Technologies | GOTHENBURG, SWEDEN / ACCESSWIRE / May 19, 2022 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL) (FRA:3XV) The CHU Toulouse hospital in France has introduced both a liver and a lung machine perfusion program, now having the ability to significant... |
| 27.04.2022 | XVIVO Submits an IDE Application to US FDA for Its Innovative Heart Technology – a Significant Milestone | GOTHENBURG, SE / ACCESSWIRE / April 27, 2022 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) XVIVO proudly announces the filing of an Investigational Device Exemption (IDE) application to the US Food & Drug Administration (FDA). It ... |
| 25.04.2022 | XVIVO Presents Interim Report January-March 2022 | GOTHENBURG, SWEDEN / ACCESSWIRE / April 25, 2022 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Strong sales growth and key milestones achieved First quarter 2022 (1 Jan - 31 Mar) • Net sales amounted to SEK 92.7 million (58.3), corres... |
| 24.03.2022 | Notice to attend the annual general meeting in XVIVO Perfusion AB (publ) | GOTHENBURG, SE / ACCESSWIRE / March 24, 2022 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) The shareholders in XVIVO Perfusion AB (publ), reg. no. 556561-0424 (the "Company" or "XVIVO"), with its registered office ... |
| 23.03.2022 | XVIVO Obtains Its First Certificate Under EU Medical Device Regulation (MDR) for Kidney Assist Transport | GOTHENBURG, SE / ACCESSWIRE / March 23, 2022 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Today XVIVO announces an important milestone as the company receives the EU MDR certification for Kidney Assist Transport - a transportable org... |